Chimera Research Group Critical Minerals Equity Note LibertyStream Infrastructure Partners Inc. (TSXV: LIB | OTCQB: VLTLF) Company Update: De-Risking Event – From Lab to First Commercial Lithium Carbonate Production in The Field. Author: Joe Gantos, Senior Analyst Date: December 2nd, 2025 Recommendation: STRONG BUY Target Price (12-18 mo): C$3.00 – C$5.00 Current Price: C$0.85 Market […]
November 4th Biotech Update
The sector remains volatile even as it seems to have emerged from the recent depression in the sector. There will be periods of increase volatility and pullbacks but I still think we have emerged from the doldrums and the general movement going forward will be higher even if we do have some periods of negative […]
October 27th Biotech Update
Some fireworks to start the week, although the news came out yesterday about the large deal. The more we see deals with continued lower movement of rates and the more we get some regulatory consistency, the better for the sector. Ideally we would like to see the government re-open to get the FDA working again […]
LibertyStream Infrastructure Partners – The Permian Brine Disruptor Poised for Commercial Liftoff
Chimera Research Group Critical Minerals Equity Note LibertyStream Infrastructure Partners Inc. (TSXV: LIB | OTCQB: VLTLF) Company Update: 14-Month De-Risking Sprint – From Lab to Commercial Scale in Record Time Author: Joe Gantos, Senior Analyst Date: October 27ᵗʰ, 2025 Recommendation: STRONG BUY Target Price (12-18 mo): C$3.00 – C$5.00 Current Price: C$.48 Market Cap: ~C$84 […]
Cardiol Therapeutics Unlocking Potential in Heart-Failure Therapy Through Significant LV Mass Reduction – A Comprehensive Report
Cardiol Therapeutics Inc. (NASDAQ/TSX: CRDL), a clinical-stage biopharmaceutical company specializing in anti-inflammatory and anti-fibrotic therapies for heart disease, has demonstrated promising proof-of-concept data from its Phase II ARCHER trial of CardiolRx™ in acute myocarditis. The trial's topline results, announced on August 6, 2025, highlight a “significant reduction in left ventricular (LV) mass”, a critical biomarker […]
October 16th Biotech Update
News continues to be generally positive for the sector and there is no reason to suspect that the broader trend for the sector will be higher. Obviously, there will be retrenchments and pullbacks but those will be opportunities to add to positions just as the rallies in the bear market were opportunities to trim positions. […]
October 14th Biotech Update
Over the past few days, biotech and pharmaceutical stocks have seen mixed but generally positive moves sparked by deal news and strong individual performers. This environment reinforces the more positive sentiment around the sector but with a preference now being placed on pipelines with strong differentiation, regulatory path clarity, or acquisition potential. It seems the […]
October 10th Biotech Update
There is a lot still to summarize and talk about and I will be slowly chipping away at what I see are key developments for the broader market as well as those companies I have followed in the past. This has a little bit of both to end the week. BTIG hosted a webcast with […]
October 8th Biotech Update
Biotech sentiment is cautiously constructive: the XBI is up about 15% year-to-date which is outpacing the broader health sector. While we have seen deals, the next stage would be the IPO window creaking open again—2025 has logged ~165 U.S. IPOs across sectors and fresh biopharma filings like BillionToOne point to improving risk appetite, even if […]
October 6th Biotech Update
It has been a little while but my job has been quite busy but I am going to get back into a rhythm of putting out notes. To be fair, the market has done better without me and it finally seems like sentiment has turned. Deals, data, rates, and reduced uncertainty have all either moved […]
Eupraxia’s EP-104GI Demonstrates Unprecedented Durability in EoE at One-Year Follow-Up
Eupraxia Pharmaceuticals Inc. (EPRX) – Investment Snapshot Date: September 02, 2025 Stock Price: US$5.48 | Market Cap: US$198M (as of 09/02/2025) Recommendation: Buy | Target Price: US$12.00 On September 2, 2025, Eupraxia Pharmaceuticals ($EPRX) released one-year results from Cohort 5 (48 mg dose, 12 injections of 4 mg each) of the Phase 1b/2a RESOLVE trial, […]
Advancing EoE Treatment Amid Biologic Setbacks: CLDX Failure Reinforces EPRX’s Edge
Eupraxia Pharmaceuticals Inc. (EPRX) – Investment Snapshot Date: August 20, 2025 Stock Price: US$5.39 | Market Cap: US$193M (as of 8/19/2025 close) Recommendation: Buy | Target Price: $12.00 On August 19, 2025, Celldex Therapeutics (CLDX) announced results from its Phase 2 trial of barzolvolimab in EoE. The monoclonal antibody (mAb) targeting KIT met its primary […]
Eupraxia Phase 2b RESOLVE Trial Update: A Promising Step Forward for EoE Treatment
Eupraxia Pharmaceuticals Inc. (EPRX) – Investment Snapshot Stock Price: US$5.40 | Market Cap: ~US$194M Recommendation: Buy | Target Price: US$12.00 On July 8, 2025, Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX, TSX: EPRX) announced a significant milestone in its clinical development program, dosing the first patient in the placebo-controlled Phase 2b portion of the RESOLVE trial for […]
July 22nd Biotech Update
There has been a lot of movement in the market, but I would rather focus on the bigger picture and news that could really have larger implications. I think M&A has picked up and will continue to be a story but that has not been the news recently. SRPT has been the most dramatic […]
June 24th Biotech Update
Looks like events are settling down in the Middle East and while there are still risks, it looks like everyone is taking the offramps (for now). This should decrease the price of oil and increase the risk tolerance of the market. Of course, the sector did not do great when it appeared to settle down […]
June 18th Biotech Update
I feel worried saying this but the sector is doing well at least when one looks at the chart. This certainly does not mean that the headwinds and concerns are suddenly going away but bull markets are built on climbing a wall of worries and there are a lot of worries that could be climbed […]
June 16 Biotech Update
Despite all of the news in the market recently, we actually seem to be in a good place (at least as I look at the chart). If you take a step back, we are around 20% higher since the panic lows and there can be what looks like trend higher. There are higher highs and […]
Conavi Is Revolutionizing Coronary Interventions
I’ve primarily been focused on biotech stocks and have generally avoided medical device investments. But a month ago, a broker I’ve worked with for years called me about a new opportunity. He knows I’m selective, but he was excited about the company and wanted my take on their public financing round. When he mentioned it […]
May 22nd Biotech Update
Nothing is ever clean in the sector (at least over the past couple of years). What could have been a nice move to higher highs has been put on pause. This is not to say that is off the table or that the sector has broken down as that is not the case at all. […]
April 21st Biotech Update
It has been a little wild in the sector in terms of news (MFN pricing executive order) but if you take a step back and look at the chart, it does not look nearly as bad as it sounded when the announcement happened. Just imagine that you know nothing of the news and look at […]
